midodrine has been researched along with Dizziness in 9 studies
Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.
midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.
Dizziness: An imprecise term which may refer to a sense of spatial disorientation, motion of the environment, or lightheadedness.
Excerpt | Relevance | Reference |
---|---|---|
"We assessed the potency of octreotide and midodrine, and their combination, in the treatment of the postural tachycardia syndrome (POTS) and orthostatic intolerance (OI)." | 9.12 | Treatment of postural tachycardia syndrome: a comparison of octreotide and midodrine. ( Bryner, KD; Hobbs, G; Hoeldtke, ME; Hoeldtke, RD, 2006) |
"Other than scalp paresthesia in one patient, no adverse effects were noted." | 5.30 | Intradialytic hypotension: is midodrine beneficial in symptomatic hemodialysis patients? ( Cruz, DN; Mahnensmith, RL; Perazella, MA, 1997) |
"We assessed the potency of octreotide and midodrine, and their combination, in the treatment of the postural tachycardia syndrome (POTS) and orthostatic intolerance (OI)." | 5.12 | Treatment of postural tachycardia syndrome: a comparison of octreotide and midodrine. ( Bryner, KD; Hobbs, G; Hoeldtke, ME; Hoeldtke, RD, 2006) |
"A total of 171 patients with orthostatic hypotension participated in a multicenter, randomized, placebo-controlled study." | 2.68 | Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. ( Freeman, R; Gilden, JL; Low, PA; McElligott, MA; Sheng, KN, 1997) |
"Orthostatic hypotension is defined as a decrease in blood pressure of 20 mm Hg or more systolic or 10 mm Hg or more diastolic within three minutes of standing from the supine position or on assuming a head-up position of at least 60 degrees during tilt table testing." | 1.72 | Orthostatic Hypotension: A Practical Approach. ( Farrell, J; Kim, MJ, 2022) |
"In case of orthostatic hypotension with an insufficient increase in heart rate, one has to consider autonomic dysfunction." | 1.72 | [Dizziness upon standing: consider autonomic dysfunction]. ( Bloem, BR; Deinum, J; Riksen, NP; Rutten, J, 2022) |
"Other than scalp paresthesia in one patient, no adverse effects were noted." | 1.30 | Intradialytic hypotension: is midodrine beneficial in symptomatic hemodialysis patients? ( Cruz, DN; Mahnensmith, RL; Perazella, MA, 1997) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (11.11) | 18.7374 |
1990's | 3 (33.33) | 18.2507 |
2000's | 1 (11.11) | 29.6817 |
2010's | 2 (22.22) | 24.3611 |
2020's | 2 (22.22) | 2.80 |
Authors | Studies |
---|---|
Kim, MJ | 1 |
Farrell, J | 1 |
Riksen, NP | 1 |
Rutten, J | 1 |
Bloem, BR | 1 |
Deinum, J | 1 |
Tanabe, N | 1 |
Takane, K | 1 |
Yokoyama, K | 1 |
Tanno, Y | 1 |
Yamamoto, I | 1 |
Ohkido, I | 1 |
Yokoo, T | 1 |
Wecht, JM | 1 |
Radulovic, M | 1 |
Rosado-Rivera, D | 1 |
Zhang, RL | 1 |
LaFountaine, MF | 1 |
Bauman, WA | 1 |
Hoeldtke, RD | 1 |
Bryner, KD | 1 |
Hoeldtke, ME | 1 |
Hobbs, G | 1 |
Low, PA | 2 |
Gilden, JL | 2 |
Freeman, R | 2 |
Sheng, KN | 2 |
McElligott, MA | 2 |
Cruz, DN | 1 |
Mahnensmith, RL | 1 |
Perazella, MA | 1 |
Sütsch, G | 1 |
Vetter, W | 1 |
Hess, OM | 1 |
Rhyner, K | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Prevention of Low Blood Pressure in Persons With Tetraplegia[NCT00237770] | Phase 2/Phase 3 | 16 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury[NCT03602014] | Phase 4 | 22 participants (Actual) | Interventional | 2018-06-01 | Completed | ||
A Dose Response Trial Using 5 and 10 mg. of Midodrine Hydrochloride to Treat Orthostatic Hypotension in Persons With SCI[NCT00426842] | Phase 2 | 11 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
Safety and Efficacy of L-NAME and Midodrine to Increase MAP in Persons With Tetraplegia[NCT00835224] | Phase 2 | 34 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
Clinical Laboratory Evaluation of Primary Chronic Autonomic Failure[NCT00059033] | 325 participants (Actual) | Observational | 2003-04-10 | Terminated | |||
Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study[NCT02308124] | Phase 4 | 87 participants (Actual) | Interventional | 2014-11-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Average systolic blood pressure over 45 minutes at 45 degrees of head-up tilt. (NCT00237770)
Timeframe: Average systolic blood pressure during head-up tilt (45 degrees) comparing active drug (L-NAME: 1.0 and 2.0 mg/kg) to placebo.
Intervention | mmHg (Mean) |
---|---|
Tetraplegic Systolic Blood Pressure Responses to Placebo | 91.80 |
Control Systolic Blood Pressure Responses to Placebo | 108.10 |
Tetraplegic Systolic Blood Pressure Responses to L-NAME 1.0 mg | 112.04 |
Tetraplegic Systolic Blood Pressure Responses to L-NAME 2.0 mg | 129.94 |
brachial artery systolic blood pressure (mmHg) (NCT00426842)
Timeframe: The difference between the average supine systolic blood pressure and the average systolic blood pressure at 45 degree head-up tilt position.
Intervention | mmHg (Mean) | |
---|---|---|
Baseline Blood Pressure | Head-up Tilt Blood Pressure | |
Midodrine 10 mg | 102 | 109 |
Midodrine 5 mg | 97 | 96 |
No-drug | 98 | 87 |
(NCT00835224)
Timeframe: Blood pressure during the 4 hour period after no drug, L-NAME (IV: 1.0 mg/kg) and midodrine (PO: 10.0 mg) administration
Intervention | mmHg (Mean) |
---|---|
Arm 1A | 120 |
Arm 1B | 112 |
Arm 2A | 117 |
Arm 2B | 109 |
Arm 3A | 96 |
Arm 3B | 109 |
"Change of the depression score after 3-month medical treatment compared to initial results.~21 multiple-choice questions, each of which can be scored from 0 to 3. Higher score represent higher degree of depression.~Score Normal; 0-13, Mild depression; 14-19, Moderate depression; 20-28, Severe depression; 29-63" (NCT02308124)
Timeframe: after 3-month medical treatment.
Intervention | points (Mean) |
---|---|
Midodrine Only | -6.8 |
Pyridostigmine Only | -7.8 |
Midodrine + Pyridostigmine | -3.5 |
"Change of the OH associated symptom survey result after 3-month medical treatment compared to initial results.~OHQ questionnaire has two components: the OH daily activity scale (OHDAS), which contains 4 items measuring the impact of OH on daily activities, and the OH symptom assessment (OHSA), which contains 6 items measuring the symptoms of OH (dizziness/light headedness, vision disturbance, weakness, fatigue, trouble concentrating, and head/neck discomfort).This questionnaire reflects the severity of OH-related symptoms on a 10-point scale, with 0 indicating the absence of a symptom and 10 indicating maximal severity.~** OHQ total score minimal 0 ~ maximal 100" (NCT02308124)
Timeframe: after 3-month medical treatment.
Intervention | points (Mean) |
---|---|
Midodrine Only | -16.2 |
Pyridostigmine Only | -17.2 |
Midodrine + Pyridostigmine | -12.6 |
"changes in Short Form (36) Health Survey version 2 (SF-36v2) mental component summary scale (MCS)~SF-36v2 measures eight HRQOL domains (physical functioning, role limitation caused by physical problems, bodily pain, general health, vitality, social functioning, role limitation caused by emotional problems, and mental health) summarized into two summary scales that are normalized to the population (mean=50, standard deviation=10): the physical component summary scale (PCS) and the mental component summary scale (MCS).20 Better HRQOL is reflected by higher SF-36v2 scores." (NCT02308124)
Timeframe: changes at 3 months after treatment
Intervention | points (Mean) |
---|---|
Midodrine Only | 5.0 |
Pyridostigmine Only | 6.7 |
Midodrine + Pyridostigmine | 0.4 |
"changes in Short Form (36) Health Survey version 2 (SF-36v2) physical component summary scale (PCS) compared to the baseline~SF-36v2 measures eight HRQOL domains (physical functioning, role limitation caused by physical problems, bodily pain, general health, vitality, social functioning, role limitation caused by emotional problems, and mental health) summarized into two summary scales that are normalized to the population (mean=50, standard deviation=10): the physical component summary scale (PCS) and the mental component summary scale (MCS).20 Better HRQOL is reflected by higher SF-36v2 scores." (NCT02308124)
Timeframe: changes at 3 months after treatment
Intervention | points (Mean) |
---|---|
Midodrine Only | 5.6 |
Pyridostigmine Only | 4.2 |
Midodrine + Pyridostigmine | 2.7 |
Change of orthostatic SBP and DBP drop after 3-month medical treatment compared to initial results. (NCT02308124)
Timeframe: after 3-month medical treatment
Intervention | mmHg (Mean) | |
---|---|---|
Changes in SBP drop | Changes in DBP drop | |
Midodrine + Pyridostigmine | 8.9 | 7.4 |
Midodrine Only | 11.1 | 7.5 |
Pyridostigmine Only | 13.6 | 11.1 |
2 trials available for midodrine and Dizziness
Article | Year |
---|---|
Treatment of postural tachycardia syndrome: a comparison of octreotide and midodrine.
Topics: Adult; Blood Pressure; Data Interpretation, Statistical; Dizziness; Drug Therapy, Combination; Femal | 2006 |
Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group.
Topics: Activities of Daily Living; Adrenergic alpha-Agonists; Analysis of Variance; Dizziness; Double-Blind | 1997 |
Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group.
Topics: Activities of Daily Living; Adrenergic alpha-Agonists; Analysis of Variance; Dizziness; Double-Blind | 1997 |
Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group.
Topics: Activities of Daily Living; Adrenergic alpha-Agonists; Analysis of Variance; Dizziness; Double-Blind | 1997 |
Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group.
Topics: Activities of Daily Living; Adrenergic alpha-Agonists; Analysis of Variance; Dizziness; Double-Blind | 1997 |
7 other studies available for midodrine and Dizziness
Article | Year |
---|---|
Orthostatic Hypotension: A Practical Approach.
Topics: Accidental Falls; Adolescent; Adult; Aged; Blood Pressure; Chest Pain; Diabetes Mellitus; Diet; Dizz | 2022 |
[Dizziness upon standing: consider autonomic dysfunction].
Topics: Aged; Autonomic Nervous System Diseases; Blood Pressure; Dizziness; Humans; Hypotension, Orthostatic | 2022 |
Dialysate temperature adjustment as an effective treatment for baroreflex failure syndrome in hemodialysis patient.
Topics: Aged; Baroreflex; Carotid Sinus; Cold Temperature; Dialysis Solutions; Dizziness; Droxidopa; Enteral | 2014 |
Orthostatic effects of midodrine versus L-NAME on cerebral blood flow and the renin-angiotensin-aldosterone system in tetraplegia.
Topics: Adult; Cerebrovascular Circulation; Dizziness; Female; Hemodynamics; Humans; Male; Middle Aged; Mido | 2011 |
Orthostatic effects of midodrine versus L-NAME on cerebral blood flow and the renin-angiotensin-aldosterone system in tetraplegia.
Topics: Adult; Cerebrovascular Circulation; Dizziness; Female; Hemodynamics; Humans; Male; Middle Aged; Mido | 2011 |
Orthostatic effects of midodrine versus L-NAME on cerebral blood flow and the renin-angiotensin-aldosterone system in tetraplegia.
Topics: Adult; Cerebrovascular Circulation; Dizziness; Female; Hemodynamics; Humans; Male; Middle Aged; Mido | 2011 |
Orthostatic effects of midodrine versus L-NAME on cerebral blood flow and the renin-angiotensin-aldosterone system in tetraplegia.
Topics: Adult; Cerebrovascular Circulation; Dizziness; Female; Hemodynamics; Humans; Male; Middle Aged; Mido | 2011 |
Orthostatic effects of midodrine versus L-NAME on cerebral blood flow and the renin-angiotensin-aldosterone system in tetraplegia.
Topics: Adult; Cerebrovascular Circulation; Dizziness; Female; Hemodynamics; Humans; Male; Middle Aged; Mido | 2011 |
Orthostatic effects of midodrine versus L-NAME on cerebral blood flow and the renin-angiotensin-aldosterone system in tetraplegia.
Topics: Adult; Cerebrovascular Circulation; Dizziness; Female; Hemodynamics; Humans; Male; Middle Aged; Mido | 2011 |
Orthostatic effects of midodrine versus L-NAME on cerebral blood flow and the renin-angiotensin-aldosterone system in tetraplegia.
Topics: Adult; Cerebrovascular Circulation; Dizziness; Female; Hemodynamics; Humans; Male; Middle Aged; Mido | 2011 |
Orthostatic effects of midodrine versus L-NAME on cerebral blood flow and the renin-angiotensin-aldosterone system in tetraplegia.
Topics: Adult; Cerebrovascular Circulation; Dizziness; Female; Hemodynamics; Humans; Male; Middle Aged; Mido | 2011 |
Orthostatic effects of midodrine versus L-NAME on cerebral blood flow and the renin-angiotensin-aldosterone system in tetraplegia.
Topics: Adult; Cerebrovascular Circulation; Dizziness; Female; Hemodynamics; Humans; Male; Middle Aged; Mido | 2011 |
Orthostatic effects of midodrine versus L-NAME on cerebral blood flow and the renin-angiotensin-aldosterone system in tetraplegia.
Topics: Adult; Cerebrovascular Circulation; Dizziness; Female; Hemodynamics; Humans; Male; Middle Aged; Mido | 2011 |
Orthostatic effects of midodrine versus L-NAME on cerebral blood flow and the renin-angiotensin-aldosterone system in tetraplegia.
Topics: Adult; Cerebrovascular Circulation; Dizziness; Female; Hemodynamics; Humans; Male; Middle Aged; Mido | 2011 |
Orthostatic effects of midodrine versus L-NAME on cerebral blood flow and the renin-angiotensin-aldosterone system in tetraplegia.
Topics: Adult; Cerebrovascular Circulation; Dizziness; Female; Hemodynamics; Humans; Male; Middle Aged; Mido | 2011 |
Orthostatic effects of midodrine versus L-NAME on cerebral blood flow and the renin-angiotensin-aldosterone system in tetraplegia.
Topics: Adult; Cerebrovascular Circulation; Dizziness; Female; Hemodynamics; Humans; Male; Middle Aged; Mido | 2011 |
Orthostatic effects of midodrine versus L-NAME on cerebral blood flow and the renin-angiotensin-aldosterone system in tetraplegia.
Topics: Adult; Cerebrovascular Circulation; Dizziness; Female; Hemodynamics; Humans; Male; Middle Aged; Mido | 2011 |
Orthostatic effects of midodrine versus L-NAME on cerebral blood flow and the renin-angiotensin-aldosterone system in tetraplegia.
Topics: Adult; Cerebrovascular Circulation; Dizziness; Female; Hemodynamics; Humans; Male; Middle Aged; Mido | 2011 |
Orthostatic effects of midodrine versus L-NAME on cerebral blood flow and the renin-angiotensin-aldosterone system in tetraplegia.
Topics: Adult; Cerebrovascular Circulation; Dizziness; Female; Hemodynamics; Humans; Male; Middle Aged; Mido | 2011 |
Intradialytic hypotension: is midodrine beneficial in symptomatic hemodialysis patients?
Topics: Administration, Oral; Adrenergic alpha-Agonists; Aged; Aged, 80 and over; Blood Pressure; Diastole; | 1997 |
Efficacy of midodrine for neurogenic orthostatic hypotension. Reply.
Topics: Adrenergic alpha-Agonists; Dizziness; Humans; Hypotension, Orthostatic; Midodrine; Vasoconstrictor A | 1997 |
[Dizziness, syncope, orthostatic hypotension].
Topics: Aged; Dizziness; Epinephrine; Female; Humans; Hypotension, Orthostatic; Midodrine; Norepinephrine; S | 1988 |